StockData
Ovid Therapeutics Inc. logo

Ovid Therapeutics Inc. (OVID) stock

OVIDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 10/30
$2.22−0.18 (-7.50%)

Close on Nov 17, 2026Market cap $433.56MP/E –Yield –

Earnings

Ovid Therapeutics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Mar 17, 2027
Q4 FY2026 · estimated, before the open
Revenue, Q3 FY2026
–
EPS, Q3 FY2026
-$0.10
-$0.17 a year earlier
Latest guidance
Issued
Nov 10, 2021 · 1 item

Quarterly results

Revenue and earnings per share from each of Ovid Therapeutics's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q4 FY2026ended Dec 31, 2026Mar 17, 2027Expected––––
Q3 FY2026ended Sep 30, 2026Nov 10, 2026before the open––-$0.10Release
Q4 FY2025ended Dec 31, 2025Mar 18, 2026before the open$700.00K+821.1%$0.06Release
Q3 FY2025ended Sep 30, 2025Nov 12, 2025before the open––-$0.17Release
Q1 FY2025ended Mar 31, 2025May 13, 2025before the open––-$0.14Release
Q4 FY2024ended Dec 31, 2024Mar 11, 2025before the open$76.00K–-$0.13Release
Q1 FY2024ended Mar 31, 2024May 14, 2024before the open––-$0.17Release
Q4 FY2023ended Dec 31, 2023Mar 8, 2024before the open––-$0.22Release
Q3 FY2023ended Sep 30, 2023Nov 3, 2023before the open––-$0.16Release
Q2 FY2023ended Jun 30, 2023Aug 4, 2023before the open$75.00K–-$0.18Release
Q1 FY2023ended Mar 31, 2023May 5, 2023before the open$66.16K-95.3%-$0.19Release
Q4 FY2022ended Dec 31, 2022Mar 13, 2023before the open$46.28K–-$0.16Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

No open guidance: every period Ovid Therapeutics guided for has been reported

Guidance history

Every forecast Ovid Therapeutics put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 10, 2021non-GAAP adjusted operating expensesQ4 FY2021$8.00M – $10.00MNew

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Press releases

Releases Ovid Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. News
  4. Results
  5. News
  6. News
  7. Results
  8. Results
  9. News
  10. Update
  11. Results
  12. Results
  13. Results
  14. Update
  15. News

See a number that looks wrong?